甲氨蝶呤联合米非司酮应用于异位妊娠保守治疗的临床疗效观察

来源 :中国实用医药 | 被引量 : 0次 | 上传用户:wuhanchi
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的探讨甲氨蝶呤联合米非司酮应用于异位妊娠保守治疗的临床疗效。方法选取2011年2月~2013年2月本院收治的异位妊娠行保守治疗的患者80例作为研究对象,按照随机数表法将患者随机分为观察组和对照组,每组各40例。观察组采用甲氨蝶呤联合米非司酮治疗,对照组单独应用米非司酮治疗,比较两组患者临床疗效。结果观察组总有效率显著优于对照组,组间差异有统计学意义(P<0.05)。结论甲氨蝶呤联合米非司酮应用于异位妊娠保守治疗临床疗效明确且不良反应少,是一种理想的治疗方案。 Objective To investigate the clinical efficacy of methotrexate combined with mifepristone in the conservative treatment of ectopic pregnancy. Methods Twenty patients with conservative treatment of ectopic pregnancy treated in our hospital from February 2011 to February 2013 were selected as the research objects. According to random number table, the patients were randomly divided into observation group and control group, with 40 cases in each group . The observation group was treated with methotrexate combined with mifepristone, while the control group was treated with mifepristone alone. The clinical efficacy was compared between the two groups. Results The total effective rate of the observation group was significantly better than that of the control group, the difference was statistically significant (P <0.05). Conclusion Methotrexate combined with mifepristone in the conservative treatment of ectopic pregnancy with clear clinical efficacy and fewer adverse reactions, is an ideal treatment.
其他文献
期刊
1目的rn渥太华声明旨在为临床试验注册建立国际认可的标准(第Ⅰ部分),以及根据这一标准提议的操作方案(第Ⅱ部分).
期刊
随着新千年第一个十年在2011年的新年钟声中精彩落幕,中国的循证医学也为它在新世纪前十年的发展画上了一个圆满的句号:rn这一年,以世界卫生组织(WHO)为首的卫生行政部门从经